These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29735424)

  • 21. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.
    Thompson GR; Wiederhold NP
    Mycopathologia; 2010 Nov; 170(5):291-313. PubMed ID: 20524153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
    Kovanda LL; Desai AV; Lu Q; Townsend RW; Akhtar S; Bonate P; Hope WW
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4568-76. PubMed ID: 27185799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
    Denis J; Ledoux MP; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.
    Espinel-Ingroff A; Chowdhary A; Gonzalez GM; Lass-Flörl C; Martin-Mazuelos E; Meis J; Peláez T; Pfaller MA; Turnidge J
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3823-8. PubMed ID: 23716059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
    Seyedmousavi S; Brüggemann RJ; Meis JF; Melchers WJ; Verweij PE; Mouton JW
    Antimicrob Agents Chemother; 2015 May; 59(5):2855-66. PubMed ID: 25753636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
    Espinel-Ingroff A; Chowdhary A; Gonzalez GM; Guinea J; Hagen F; Meis JF; Thompson GR; Turnidge J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):666-8. PubMed ID: 25313209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
    Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
    Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
    Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
    J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients.
    Lahmer T; Batres Baires G; Heilmaier M; Schmid RM; Sörgel F; Kinzig M; Huber W; Mayr U; Rasch S
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
    Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
    Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.